ArticlePlastic and reconstructive surgery. Global open2025
Early Outcomes Using TIGR Mesh in Direct-to-Implant Breast Reconstruction.
Article in Plastic and reconstructive surgery. Global open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Early Performance of a Multifilament Resorbable Synthetic Mesh in Aesthetic Breast Surgery: A 206 Patient Experience.Aesthetic surgery journal. Open forum · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Direct-to-implant (DTI) breast reconstruction often uses soft tissue support to improve outcomes and reduce implant migration. Synthetic meshes, such as TIGR Matrix, have emerged as potential alternatives to biological materials due to lower costs and complication rates. This study reviewed early outcomes using TIGR Matrix in immediate DTI reconstruction. Methods: A retrospective chart review was conducted on patients who underwent implant-based reconstruction with TIGR Matrix between November 2023 and June 2024 across 2 institutions. Inclusion criteria included DTI reconstruction with at least 6 months of follow-up. Data collected included demographics, oncological and reconstructive details, comorbidities, and postoperative complications. Statistical analysis was performed using MATLAB with Results: Seventy-one patients (109 breasts) met inclusion criteria. The cohort included 42.2% nipple-sparing, 40.4% skin-sparing, and 11.0% Goldilocks mastectomies. The mean patient age was 52 years. The mean time to first postoperative follow-up was 8.3 days. Major complications included 6 hematomas (5.5%), 3 seromas (2.8%), 2 infections (1.8%), and 3 explantations (2.8%). Eleven (10.1%) patients required reoperation due to complications including infection, necrosis, or residual disease. Minor complications (delayed wound healing, eschar) were observed in 17.4% of breasts. The overall complication rate excluding minor events was 12.8%. Conclusions: TIGR Matrix demonstrates an acceptable early complication profile in DTI breast reconstruction and may serve as a cost-effective alternative to acellular dermal matrices. Additional studies are needed to assess long-term outcomes and comparative effectiveness.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.